Kristen E Limbach
Overview
Explore the profile of Kristen E Limbach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu T, Dillon J, Maluccio M, Quelle D, Nash S, Cho H, et al.
J Cancer Res Clin Oncol
. 2024 Nov;
150(11):485.
PMID: 39488644
Purpose: Renal and hematological toxicity are side effects and dose-limiting factors of Peptide Receptor Radionuclide Therapy (PRRT). We aimed to assess the changes in renal and hematological function and associations...
2.
Mahuron K, Limbach K, Hernandez M, Ituarte P, Li D, Kessler J, et al.
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274193
: Although survival outcomes for neuroendocrine liver metastases (NETLM) are improved with liver-direct therapies (LDT), including hepatic debulking and nonsurgical trans-arterial embolization, the benefit is less established in the setting...
3.
Limbach K, Mahuron K, Scott A, Ituarte P, Singh G
J Clin Med
. 2023 Dec;
12(24).
PMID: 38137715
Bone metastases from gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) have been associated with poor prognosis, but it is unclear whether patients with concurrent bone metastases who receive liver-directed therapy (LDT) would derive...
4.
Limbach K, Wen W, Xing Q, Yan J, Yim J
Surgery
. 2022 Oct;
173(1):12-18.
PMID: 36207198
Background: The mammalian target of rapamycin inhibition has been shown to prolong progression-free survival in patients with pancreatic neuroendocrine tumors. The natural compound baicalein indirectly inhibits the mammalian target of...
5.
Wonn S, Ratzlaff A, Pommier S, Limbach K, Bassale S, McCully B, et al.
Am J Surg
. 2021 Mar;
221(6):1135-1140.
PMID: 33785207
Background: The 8th edition AJCC Staging for small bowel neuroendocrine tumors created a novel N2 classification. This study investigates if it is independently prognostic. Methods: Records of patients from 2008...
6.
Wonn S, Limbach K, Pommier S, Ratzlaff A, Leon E, McCully B, et al.
Surgery
. 2020 Jun;
169(1):168-174.
PMID: 32473829
Background: This study determines how much cytoreduction for small bowel neuroendocrine tumors with peritoneal carcinomatosis and liver metastases can be achieved and the corresponding survival benefits of different levels of...
7.
Limbach K, Pommier R
Surg Oncol Clin N Am
. 2020 Mar;
29(2):281-292.
PMID: 32151361
The chief causes of death of patients with GEPNETs are liver failure from hepatic replacement by tumor in the majority and bowel obstruction in the remainder. Many patients are with...
8.
Limbach K, Pommier S, Dewey E, Leon E, Pommier R
Am J Surg
. 2020 Mar;
219(5):795-799.
PMID: 32145918
Introduction: Neuroendocrine tumors (NETs) metastatic to the ovary are traditionally considered rare, but data are lacking. This study seeks to better characterize the prevalence and outcomes of patients with neuroendocrine...
9.
Limbach K, Leon E, Pommier R, Pommier S
Breast J
. 2020 Feb;
26(5):1069-1070.
PMID: 32057168
No abstract available.
10.
Limbach K, Pommier S, Massimino K, Pommier R, Naik A
Am J Surg
. 2019 Aug;
219(1):8-14.
PMID: 31375247
Background: The opioid epidemic has necessitated increased attention to prescribing practices. This study seeks to prospectively quantify postoperative opioid use after breast operation. Methods: Consecutive patients undergoing breast operation at...